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Introduction
The increase in cancer incidence in premenopausal patients 
and the significant improvement in their prognosis have 
brought concerns about the possible consequences of the 
treatment on their reproductive life.1 The most relevant side 
effect of chemotherapy for younger cancer survivors is the 
induced transient or permanent amenorrhea with resultant 
vasomotor symptoms and distress related to the concern about 
infertility.2
In addition, many young women have not been mothers yet 
at the time of cancer diagnosis, but they wish to have children 
after the end of treatments.3
Therefore, according to international guidelines, the risk of 
developing chemotherapy-induced premature ovarian insuffi-
ciency (POI) should be discussed after diagnosis with all young 
patients, before anticancer treatments.4,5 For young patients 
interested in preserving their fertility, the standard available 
strategies (ie, embryo and oocyte cryopreservation) should be 
primarily proposed, although these strategies cannot prevent 
the risk of iatrogen POI with its associated psychosocial and 
menopause-related concerns.
A pharmacological protection of the ovaries induced by the 
administration of gonadotropin-releasing hormone agonist 
(GnRHa) concomitantly with chemotherapy has been studied 
as a strategy able to reduce the gonadotoxicity of chemotherapy 
by reducing the likelihood of developing POI. Although this 
topic is still debated, recent research efforts have better clarified 
the efficacy and safety of temporary ovarian suppression with 
GnRHa during chemotherapy and this strategy is recom-
mended for premenopausal breast cancer patients candidates to 
receive systemic anticancer therapies.4–6
The aim of the current review is to provide an overview on 
the protective mechanisms on ovaries induced by the adminis-
tration of GnRHa concomitantly with chemotherapy, focusing 
on the biological rationale.
Biological Rationale
During the reproductive life, there is a balance between ovar-
ian follicles in the quiescent and in the growing phase. After 
being in the preantral stage, the development of the follicle 
depends on the gonadotrophins (follicles-stimulating hor-
mone [FSH] and luteinizing hormone [LH]) that stimulate 
the proliferation of granulosa cells, the differentiation of theca 
cells and steroidogenesis.7
Ovarian toxicity caused by chemotherapy is exerted through 
different events, involving all follicular stages and cell types:
•• A direct ovarian tissue’s toxicity, primarily described for 
alkylating and platinum agents, may deplete the follicular 
pool with a dose-dose-dependent mechanism, revealed 
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by the apoptosis of primordial follicles and of pregranu-
losa cells.
•• A vascular toxicity characterized by reduction in ovarian 
blood flow and disintegration of the vessel wall may 
mediate end-organ (ie, ovarian) damage. It has been 
reported only with anthracycline exposure.
•• Direct cellular effects on various components of the 
ovary have been shown for several classes of chemother-
apies that differ on their specific cellular targets (eg, 
cytoskeleton for taxanes, DNA for anthracyclines and 
platinum compounds, antioxidant enzymes for alkylat-
ing agents, anthracyclines and platinum compounds).8,9
Therefore, pharmacological protection should reduce toxic-
ity on ovaries at various levels.
The mechanisms used by GnRHa to protect the ovarian 
function by the damage of cytotoxic agents are not fully under-
stood yet. To date, 5 different effects have been hypothesized, 
directly or indirectly (Figure 1).
Simulation of the prepubertal, hypogonadotropic 
milieu
The administration of GnRHa induces an initial release of 
gonadotropins (the “flare-up effect”) which desensitizes the 
gonadotropin-releasing hormone (GnRH) receptors on the 
pituitary gonadotropes, preventing from the pulsatile GnRH 
secretion to perform its physiological action.10 This generates 
a hypogonadotropic, prepubertal milieu, in which the follicles 
are kept in the quiescent phase, and thus less vulnerable to 
chemotherapy-induced gonadotoxicity.11 This mechanism 
has been considered controversial, because of the dogma that 
the primordial and primary follicles are not dependent on 
gonadotropin and without FSH receptors. However, the 
advanced antral follicles, which are gonadotropin-dependent, 
secrete many growth factors (such as the transforming growth 
factors superfamily, the bone morphogenic proteins, activin, 
and others), which enabled to the growing of primordial and 
primary follicles with a paracrine way. Therefore, cytotoxic 
agents promote the death of the follicles, with decreased lev-
els of estrogen and inhibin, causing the increase of FSH, and 
consequently the unidirectional way of apoptosis (the so-
called “burn-out effect of chemotherapy”). The concomitant 
administration of GnRHa and consequent decreasing of FSH 
levels lead to minimize the further recruitment of primordial 
follicles and their burn-out.10 Moreover, growing follicles 
secrete also other factors including the antimullerian hor-
mone (AMH), that can negatively regulate the primordial 
follicles pool. During chemotherapy, AMH levels decreased, 
promoting the burn-out effect of chemotherapy. Therefore, 
the administration of GnRHa prevents gonadotoxicity of 
chemotherapy on growing follicles producing AMH, limiting 
the burn-out effect. Preclinical studies conducted demon-
strated that rats treated with GnRHa and cyclophosphamide 
have decreased levels of AMH, confirming the potential pro-
tective effect of GnRHa through the regulation of AMH lev-
els during chemotherapy.12
Decrease in ovarian perfusion
The presence of elevated levels of estrogens significantly 
increases ovarian perfusion and this mechanism is inhibited by 
administration of a GnRHa. The treatment with GnRHa 
decreased the ovarian perfusion, resulting in a lower total 
Figure 1. GnRHa administration concomitantly with chemotherapy: conceivable mechanisms of ovarian protection (modified from)7. FSH indicates 
follicles-stimulating hormone; GnRHa, gonadotropin-releasing hormone agonist.
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cumulative exposure of the ovaries to the antineoplastic drugs, 
and consequently less gonadotoxicity.13
Direct effect mediated effect through the GnRH 
receptors on ovaries
This effect is poorly understood, nevertheless it has been 
observed that GnRH receptors are expressed on ovaries sur-
face, and their activation may result in a reduction of apopto-
sis, by stimulating the oocyte maturation and follicular 
destruction.14,15
Possible up-regulation of an antiapoptotic molecule
The sphingosine-1-phosphate (S1P) is an antiapoptotic mol-
ecule that acts with the inhibition of the ceramide pathway 
implicated in chemotherapy-induced apoptosis in the ovaries; 
moreover, this molecule exerts also a protective effect of the 
primordial ovarian follicles, by improving neoangiogenesis.16 
It has been observed that S1P exposure prevents cyclophos-
phamide- and doxorubicin-induced oocyte death in vivo in 
different species,17 and oocytes without expression of sphingo-
myelinase are resistant to doxorubicin-induced apoptosis in 
vitro.18 Nevertheless, no experimental evidence supports fully 
whether the GnRHa treatment activates the receptors in the 
ovaries and possibly an intraovarian increase of S1P or other 
antiapoptotic factors.
Possible protection of the ovarian germinative stem 
cells
Johnson et al19 demonstrated the presence in the ovary of germ 
line stem cells, with mitotical activity able to reconstitute the 
primordial follicle pool. This finding contradicted the funda-
ment of reproductive human biology, based on the assumption 
of a fixed reserve of germ cell in the mammalian females, with-
out the ability of renewal.
The administration of GnRHa may interact with these 
germ cells through some pathways essential for the cell growth 
and for the activation of primordial follicles after chemother-
apy exposure.20,21
Antiapoptotic effect on cumulus cells
Recently, for the first time, a culture system of ex vivo human 
immature cumulus cell-oocyte complexes was used to investi-
gate whether GnRHa administration was able to protect the 
oocytes from chemotherapy injuries become available. The 
human complexes were cultured with chemotherapy alone (ie, 
cyclophosphamide) or GnRHa alone or both. Effects of these 
treatments were evaluated on GnRH receptors, apoptosis 
pathways, ceramide pathway, and glutathione synthesis.
The authors showed that cyclophosphamide concentration 
was mainly detrimental to the cumulus cell compartment, and 
this effect was partially counteracted by GnRHa.
Furthermore, the co-administration of GnRHa and chemo-
therapy preserved the cumulus complex from a morphological 
point of view, without impact on the oocytes, thanks to the 
surrounding granulosa cells.
The authors hypothesize that GnRHa directly acts on 
cumulus cells to protect the oocytes from chemotherapy by an 
antiapoptotic effect. This is in contrast with previous data that 
excluded a protective role of GnRHa against cyclophospha-
mide in ex vivo and in vitro models of human ovary and granu-
losa cell.22 The difference may be due to the different timing of 
GnRHa administration: in fact, in the study conducted by 
Bildik, GnRHa was administered at the same time of chemo-
therapy, whereas in the study by Scaruffi et al, the incubation 
with GnRHa started 24 hours before the addiction of chemo-
therapy. Thus, a prior and longer exposure to GnRHa facilitate 
in the cumulus cells and indirectly in the oocytes the activation 
of the molecular pathways, leading to decrease ovaries toxicities 
and follicular apoptosis during chemotherapy.
In conclusion, these results supported the indirect protective 
gonadal effect of GnRHa treatment concomitantly with chem-
otherapy, mediated through the cumulus cells (P Scaruffi et al., 
personal data).
Clinical Evidence in Breast Cancer Patients
Most studies available on the role of GnRHa during chemo-
therapy as a strategy to preserve ovarian function and potential 
fertility have been conducted in premenopausal women with 
breast cancer23–38 (Table 1).
Of 14 randomized trials, 10 reported that temporary ovar-
ian suppression with GnRHa concomitantly with chemother-
apy significantly decreased the premature ovarian failure in 
premenopausal women with breast cancer. Notably, a large het-
erogeneity among these trials should be highlighted: the tim-
ing of the assessment of the premature ovarian failure rate 
ranged from a minimum of 6 to 72 months, only few trials used 
the composite end point (amenorrhea and postmenopausal lev-
els of FSH and estradiol) to define the premature ovarian 
failure.
Furthermore, a recent meta-analysis of individual data of 
the major 5 randomized trials showed a significant reduction in 
the risk of developing POI (adjusted odds ratio = 0.38; 95% 
confidence interval [CI] = 0.26-0.57) and significant higher 
chances to be pregnant after treatments (incidence rate ratio = 
1.83; 95% CI = 1.06-3.15) in young breast cancer patients 
treated with GnRHa during chemotherapy, without impact on 
long-term outcomes.39 These results provided a substantial 
clinical evidence on the efficacy and safety of this strategy to 
improve both ovarian preservation and fertility.
Conclusions
Several efforts of research in this field were conducted through 
the last years, but the mechanism of action of GnRHa to 
induce temporary ovarian suppression is not still clearly identi-
fied. Nevertheless, recently updated guidelines on this topic 
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strongly recommend the use of temporary ovarian suppression 
with GnRHa in premenopausal breast cancer patient candi-
dates to receive chemotherapy.1,4,5
This technique has some advantages: the easy and not inva-
sive administration, the possibility to preserve not only the fer-
tility but the whole ovarian function, and finally this technique 
is not mutually exclusive with the other strategies (ie, cryo-
preservation strategies).
The administration of GnRHa should be proposed to all 
premenopausal cancer patients interested to preserve their 
ovarian function and reduce the risk of developing chemother-
apy-induced premature ovarian failure, irrespectively of their 
motherhood desire. This technique should be performed at 
least 1 week before chemotherapy, and it has the potential to 
avoid the menopausal signs and symptoms, and the detrimen-
tal long-term consequences.
However, the role of the temporary ovarian suppression 
obtained with GnRHa in the fertility preservation may be con-
sidered cautionally. Moreover, the standard cryopreservation 
strategies should be proposed for the first, and temporary ovar-
ian suppression with GnRHa should also be proposed after 
these surgical techniques.
Considering that the mechanisms of action of GnRHa to 
protect ovaries during chemotherapy are still unclear, further 
research efforts are needed to better clarify this topic.
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